Speed Expertise and Advanced Technology Save an Infant’s Heart

On April 23, 2026, news emerged of a significant medical milestone: Fletcher St. Jean, a one-year-old boy, became the youngest child to receive an extravascular implantable cardioverter-defibrillator (EV-ICD) to manage idiopathic ventricular fibrillation. The device was implanted at Cincinnati Children’s Hospital Medical Center following a life-threatening cardiac event during hospitalization for a urinary tract infection in June 2025.

Fletcher’s medical crisis began when he was just one month old. After being admitted to Cincinnati Children’s Liberty Campus for a fever and worsening condition linked to a urinary tract infection caused by E. Coli bacteria, he suffered a sudden ventricular fibrillatory arrest while under treatment. The emergency medicine team successfully revived him using an external defibrillating shock. His father, Zach St. Jean, noted that the family was fortunate the event occurred while they were already in the hospital, allowing for immediate intervention.

Following stabilization, Fletcher was transferred to Cincinnati Children’s Burnet Campus for a comprehensive evaluation to determine the cause of his cardiac arrest. Medical professionals concluded that his condition was idiopathic ventricular fibrillation, meaning no structural heart defect or identifiable cause could be found despite extensive testing. This diagnosis indicated a risk of sudden cardiac death due to unpredictable, life-threatening heart rhythms.

To protect Fletcher from future cardiac arrest, his medical team recommended an implantable cardioverter-defibrillator. Given his age and small size, a traditional transvenous ICD—which places leads inside the heart through veins—was not feasible. Instead, the team opted for an extravascular ICD, a newer type of device where the lead is placed outside the heart and veins, typically under the breastbone, reducing risks associated with venous access and long-term lead complications in infants.

Before implantation, the medical team used a 3D virtual surgery planning tool to create a detailed model of Fletcher’s chest anatomy. This technology allowed surgeons to simulate the procedure and confirm that the EV-ICD device could be safely accommodated in his small thoracic cavity. The planning process was critical given the anatomical constraints of implanting such a device in an infant.

The EV-ICD system functions by continuously monitoring the heart’s rhythm. If it detects a dangerous, life-threatening arrhythmia such as ventricular fibrillation, it delivers an electrical shock to restore a normal heartbeat. For Fletcher, this provides ongoing protection against sudden cardiac arrest, allowing him to live with significantly reduced risk of another fatal event.

As of April 2026, Fletcher is reported to be doing well. His father stated that he is active and playful, often seen toddling after his siblings, and that Notice few outward signs of his medical history. Zach St. Jean remarked that one would “almost never know that he had anything done,” reflecting the boy’s recovery and return to typical childhood activity.

The case highlights both the rarity and severity of sudden cardiac arrest in infants. While exact numbers are not precise, medical experts cited in the reports estimate that between 350 and 500 infants in the United States die each year from sudden cardiac death linked to structural heart conditions. Fletcher’s survival and treatment represent a notable advancement in pediatric cardiac care, particularly for the youngest patients who previously had limited options for long-term rhythm management.

The successful use of the EV-ICD in Fletcher St. Jean marks a significant step in expanding access to life-saving cardiac devices for infants. It underscores the role of advanced imaging, specialized pediatric expertise, and timely emergency response in treating rare but critical conditions in the youngest patients. His story contributes to growing evidence supporting the safety and efficacy of extravascular ICDs in pediatric populations where traditional approaches carry higher risks.